These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 26711775)

  • 1. Doripenem Treatment during Continuous Renal Replacement Therapy.
    Vossen MG; Wenisch JM; Maier-Salamon A; Fritsch A; Saria K; Zuba C; Jilch S; Lemmerer R; Unger M; Jaehde U; Jäger W; Thalhammer F
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1687-94. PubMed ID: 26711775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elimination of Doripenem during Dialysis and Pharmacokinetic Evaluation of Posthemodialysis Dosing for Patients Undergoing Intermittent Renal Replacement Therapy.
    Vossen MG; Ehmann L; Pferschy S; Maier-Salamon A; Haidinger M; Weiser C; Wenisch JM; Saria K; Kajahn C; Jilch S; Lemmerer R; Bécède M; Zeitlinger M; Kloft C; Jäger W; Thalhammer F
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29530855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration.
    Roberts JA; Udy AA; Bulitta JB; Stuart J; Jarrett P; Starr T; Lassig-Smith M; Roberts NA; Dunlop R; Hayashi Y; Wallis SC; Lipman J
    J Antimicrob Chemother; 2014 Sep; 69(9):2508-16. PubMed ID: 24879665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of Monte Carlo Simulations to Determine Optimal Carbapenem Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy.
    Lewis SJ; Kays MB; Mueller BA
    J Clin Pharmacol; 2016 Oct; 56(10):1277-87. PubMed ID: 26919659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of an extended 4-hour infusion of piperacillin-tazobactam in critically ill patients undergoing continuous renal replacement therapy.
    Awissi DK; Beauchamp A; Hébert E; Lavigne V; Munoz DL; Lebrun G; Savoie M; Fagnan M; Amyot J; Tétreault N; Robitaille R; Varin F; Lavallée C; Pichette V; Leblanc M
    Pharmacotherapy; 2015 Jun; 35(6):600-7. PubMed ID: 26095008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doripenem pharmacokinetics in critically ill patients receiving continuous hemodiafiltration (CHDF).
    Hidaka S; Goto K; Hagiwara S; Iwasaka H; Noguchi T
    Yakugaku Zasshi; 2010 Jan; 130(1):87-94. PubMed ID: 20046071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter Population Pharmacokinetic Study of Colistimethate Sodium and Colistin Dosed as in Normal Renal Function in Patients on Continuous Renal Replacement Therapy.
    Leuppi-Taegtmeyer AB; Decosterd L; Osthoff M; Mueller NJ; Buclin T; Corti N
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30478168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy.
    Roger C; Wallis SC; Muller L; Saissi G; Lipman J; Lefrant JY; Roberts JA
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4901-9. PubMed ID: 27270279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Population Pharmacokinetic Model-Guided Evaluation of Ceftolozane-Tazobactam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration.
    Sime FB; Lassig-Smith M; Starr T; Stuart J; Pandey S; Parker SL; Wallis SC; Lipman J; Roberts JA
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31658965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents.
    Goff DA; Nicolau DP
    Clin Ther; 2013 Jun; 35(6):766-71. PubMed ID: 23795574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population Pharmacokinetics of Doripenem in Critically Ill Patients with Sepsis in a Malaysian Intensive Care Unit.
    Abdul-Aziz MH; Abd Rahman AN; Mat-Nor MB; Sulaiman H; Wallis SC; Lipman J; Roberts JA; Staatz CE
    Antimicrob Agents Chemother; 2016 Jan; 60(1):206-14. PubMed ID: 26482304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Removal of doripenem during hemodialysis and the optimum dosing regimen for patients undergoing hemodialysis.
    Tanoue K; Nishi K; Kadowaki D; Hirata S
    Ther Apher Dial; 2011 Jun; 15(3):327-33. PubMed ID: 21624085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients.
    Isla A; Gascón AR; Maynar J; Arzuaga A; Toral D; Pedraz JL
    Clin Ther; 2005 May; 27(5):599-608. PubMed ID: 15978309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem.
    Cirillo I; Vaccaro N; Balis D; Redman R; Matzke GR
    Antimicrob Agents Chemother; 2011 Mar; 55(3):1187-93. PubMed ID: 21199922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The doripenem serum concentrations in intensive care patients suffering from acute kidney injury, sepsis, and multi organ dysfunction syndrome undergoing continuous renal replacement therapy slow low-efficiency dialysis.
    Wieczorek A; Tokarz A; Gaszynski W; Gaszynski T
    Drug Des Devel Ther; 2014; 8():2039-44. PubMed ID: 25364230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetic Analysis of Doripenem after Intravenous Infusion in Korean Patients with Acute Infections.
    Lee DH; Kim YK; Jin K; Kang MJ; Joo YD; Kim YW; Moon YS; Shin JG; Kiem S
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibiotic Dosing for Critically Ill Adult Patients Receiving Intermittent Hemodialysis, Prolonged Intermittent Renal Replacement Therapy, and Continuous Renal Replacement Therapy: An Update.
    Hoff BM; Maker JH; Dager WE; Heintz BH
    Ann Pharmacother; 2020 Jan; 54(1):43-55. PubMed ID: 31342772
    [No Abstract]   [Full Text] [Related]  

  • 18. Open-Label Study To Evaluate the Single-Dose Pharmacokinetics, Safety, and Tolerability of Doripenem in Infants Less than 12 Weeks in Chronological Age.
    Cirillo I; Vaccaro N; Castaneda-Ruiz B; Redman R; Cossey V; Bradley JS; Allegaert K
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4742-9. PubMed ID: 26014957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
    Sumitani Y; Kobayashi Y
    Jpn J Antibiot; 2007 Dec; 60(6):394-403. PubMed ID: 18447209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients with Sepsis.
    Rahbar AJ; Lodise TP; Abraham P; Lockwood A; Pai MP; Patka J; Rabinovich M; Curzio K; Chester K; Williams B; Morse B; Chaar M; Huang V; Salomone J
    Surg Infect (Larchmt); 2016 Dec; 17(6):675-682. PubMed ID: 27841954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.